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Introduction
Over the past 20 years most of the efforts in HIV vaccine
development have focused on sterilizing immunity by
targeting the Envelope protein (Env). However, results
from preclinical and clinical trials have been largely
disappointing [1–11]. Therefore, current vaccine strat-
egies are not only aimed at preventing virus infection but
also at blocking virus replication and disease onset. In
particular, the control of virus replication should provide
protection from disease development and reduce virus
transmission, halting the HIV epidemic. This objective
may be achieved by targeting virus regulatory genes,
which are expressed early after infection, are essential for
virus replication and pathogenesis, and are more
conserved among HIV clades. This approach may be
effective for both preventive and therapeutic vaccine
strategies [12–68]. In this article we review the
characteristics of Tat and why it was selected for use in a
vaccine. We also cite the lesson learned in the development
of this anti-Tat vaccine for use in human clinical trials.
Why HIV-1 Tat?
Tat represents an optimal candidate for a vaccine
controlling virus replication and blocking disease
progression (Table 1).
Role of Tat in the virus life cycle
Tat is a key viral regulatory protein produced very early
after infection, even before virus integration, and is
necessary for viral gene expression, cell-to-cell virus
transmission and disease progression [69–85]. Further-
more, Tat is released by acutely infected cells [70,86–89]
promoting HIV-1 replication [70,90,91], as well as the
recruitment and activation of uninfected cells, providing
new targets for HIV spread [61,70,87,90,92–95].
Cross-sectional and longitudinal studies of Tat
immune response in natural infection
The presence of anti-Tat antibodies appears to play a
protective role from disease progression [96–101]. In
particular, a higher prevalence of anti-Tat antibodies has
been detected in asymptomatic HIV-infected individuals
compared with progressed patients [98,100,102,103].
In addition, a cross-sectional assessment in 302 HIV-1-
infected patients showed that anti-Tat antibodies are more
frequent at an early stage (A) compared with symptomatic
stages (B or C) (Table 2), whereas no differences are
observed for antibodies directed against structural
proteins. Furthermore, a study performed in a cohort
of 252 individuals with known dates of seroconversion
and a medium follow-up of 7.2 years [105] indicated a
strong association of anti-Tat antibodies with slower
disease progression. Moreover, none of the individuals
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who were persistently anti-Tat positive progressed to
AIDS, whereas AIDS occurred in anti-Tat-negative
individuals [105].
Anti-Tat cytotoxic T lymphocytes are frequently found
in natural infection [24,106–109]. In particular, CD8
T-cell responses to Tat are more frequent in patients
controlling viraemia [106,110], and correlate with early
virus control both in humans [111,112] and monkeys
[113,114].
Tat sequence conservation among HIV clades
The immunogenic regions of Tat are conserved
among the HIV-1 M group [115–118]. Cross-clade
recognition of Tat B clade (BH-10) is observed with
sera from Ugandan, South African and Italian patients
who are infected with different subtypes [104]. In
addition, the predicted Tat amino acidic sequence
(1–86) is well conserved in its first 58 amino acids
among the circulating virus clades and in the BH-10
Tat sequence, which derives from the first isolate of
two decades ago, providing evidence that a Tat vaccine
may be used in different geographical areas of the
world [104].
Immunoregulatory properties of biologically
active Tat protein
Active Tat protein possesses immunomodulant and
adjuvant properties that are highly advantageous in
vaccine development. Native, but not oxidized, Tat
protein is selectively and very efficiently taken up by
monocyte-derived dendritic cells (MDDC) promoting
cell maturation and T helper type 1 polarization, leading
to a more efficient presentation of both allogeneic and
exogenous soluble antigens [119]. Furthermore, Tat
modifies the catalytic subunit composition of immuno-
proteasomes in B and T cells, leading to a more efficient
presentation of subdominant MHC-I-binding cytotoxic
T-lymphocyte epitopes of heterologous antigens both
in vitro and in vivo [120,121, R. Gavioli, paper in
preparation].
Absence of seroconversion in vaccinees
Being devoid of structural HIV proteins, the Tat vaccine
does not induce seroconversion, facilitating trial recruit-
ment as well as the monitoring of vaccinees.
Taken together, these data suggest that vaccination with
Tat may modify the virus–host dynamics and control
HIV-1 replication both in primary infection (preventive
strategy) and in infected individuals (therapeutic strategy).
Therefore, the active Tat protein was chosen as a vaccine
candidate against HIV/AIDS for the development of
both preventive and therapeutic strategies.
Lesson learned
Studies performed both at the level of basic and clinical
research are essential to address antigen selection and to
design innovative strategies for vaccine development.
Dissecting the role of Tat in HIV pathogenesis, exploring
its biological properties, and investigating the anti-Tat
immune response in natural infection gave a twofold gain
by both directing our attention to this regulatory protein
and providing the necessary know-how for its develop-
ment as a vaccine candidate.
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Table 1. Reasons to use the native HIV-1 Tat protein as a vaccine
candidate for HIV/AIDS.
Biologically active Tat protein
Key role in the virus life cycle (early expression and release by
infected cells) and in AIDS pathogenesis
Correlation in cross-sectional and longitudinal studies of the
anti-Tat immune responses (humoral and cellular) with
asymptomatic stage and non-progression to AIDS
Conserved immunogenic sequences among HIV-1 clades
Very efficiently taken up by dendritic cells inducing T helper
type 1 polarization (adjuvant properties)
Modifies hierarchy of cytotoxic T-lymphocyte epitopes of
heterologous antigens in favour of subdominant and cryptic
epitopes (as a result of a modification of proteasome
catalytic subunit composition)
Preservation of the seronegative status in vaccineesa
Use as both ‘preventive’ and ‘therapeutic’ vaccine
See text for explanation and references.
aTat-vaccinated individuals will be distinguished from infected indi-
viduals because the routine tests for HIV diagnosis detect only
antibodies against structural HIV antigens and not against Tat.
Table 2. Frequencies of IgG and IgM anti-Tat antibodies in individuals stratified according to HIV status, clinical stage and CD4 T-cell counts.
IgG positive/total Percentage P a IgM positive/total Percentage P a IgG and/or IgM positive/total Percentage P a
HIV status
HIV-negative 0/132 0 0/78 0 0/132 0
HIV-positive 40/302 13.2 <0.01 21/302 6.9 0.01 52/302 17.2 <0.001
Clinical stage
A 37/220 16.8 20/220 9.1 48/220 21.8
B 1/33 3.0 1/33 3.0 2/33 6.1
C 2/49 4.11 0.01 0/49 0 0.03 2/49 4.1 0.002
CD4 cell count
200 37/233 15.9 19/233 8.1 47/233 20.2
<200 3/69 4.4 0.01 2/69 2.9 0.04 5/69 7.2 0.01
aFisher’s exact test. Cross-sectional assessment of serum IgG and IgM anti-Tat antibodies in 302 HIV-1-infected patients at different disease stage
and 132 normal blood donors (negative controls). Anti-Tat humoral immunity was assessed by an algorithm combining two enzyme-linked
immunosorbent assays as previously described [104].
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Creating the structure for HIV Tat vaccine
development
The development of the Tat vaccine candidate required a
complex multidisciplinary approach, accomplished by
multiple milestones and regulated by national and
international authorities (Fig. 1). These activities included
the production of the vaccine candidate, an evaluation of its
safety, immunogenicity and efficacy in preclinical models,
dossier preparation, and approval for human use and
clinical trials. Parallel activities consisted of: (a) studies
aimed at defining the role of Tat and the Tat immune
response in natural infection to identify correlates of
protection and to validate tests to monitor vaccinees, and
(b) capacity building to conduct advanced clinical trials in
developing countries (Fig. 1). The activities undertaken
for Tat vaccine development from basic research to clinical
testing required the build up of ‘ad hoc’ structures and
expertise within the Italian public sector, which re-
presented the focus of a 10-year-long effort (Fig. 2).
Preclinical development
Tat vaccine production and characterization
The active substance of the Tat vaccine is the biologically
active recombinant Tat protein (HTLV-IIIB strain, clone
BH-10), produced in Escherichia coli and purified by heparin
sepharosechromatography followedbyhigh-pressure liquid
chromatography [70,86,122]. This product was used for in-
vitro and preclinical studies.A set of tests, which include the
determination of physicochemical, immunochemical and
biological properties, was selected to confirm the quality
and stability of the protein (Table 3 and Fig. 3). Performing
these assays is particularly relevant because Tat contains
seven cysteines and is very sensitive to oxidation [70,86],
which induces conformational changes, hampering its
biological activity as well as recognition by conformational
antibodies. For these reasons, the activityof the product was
evaluated by two assays: the rescue of a Tat-defective
provirus (rescue assay) and the uptake by MDDC
[70,86,119]. As a result of the higher level of reproducibility
and sensitivity, theuptakebyMDDChas thenbeen selected
for the release of the Tat protein batches. The reliability of
this test has been confirmed by comparing the results
obtained by testing several lots of Tat with MDDC from a
large number of normal blood donors (Fig. 4).
Preclinical testing
Safety and immunogenicity studies were conducted in
mice and monkeys with both the biologically active Tat
protein or tat DNA. The results indicated that both
approaches are safe because no local nor systemic toxicity
was detected [17,88,123–127].
Efficacy studies in cynomolgus monkeys demonstrated
that vaccination with active Tat protein can elicit a
specific and broad immune response, and can control viral
replication blocking disease progression after challenge
with the highly pathogenic cynos-grown SHIV89.6P
cy243 (Table 4) [123,124]. Of note was the fact that no
residual virus hidden in resting cells was detected in the
protected monkeys either in blood or lymph nodes, upon
two boosts with tetanus toxoid, a stimulus known to
induce virus replication [128]. Long-term protection (up
to 2 years) correlated with the presence of high and stable
humoral and cellular (CD4 and CD8 T-cell-mediated)
responses against Tat. Vaccination with the native Tat
protein thus contained viral replication in peripheral
blood and tissues, preventing the development of AIDS.
Immunization with native Tat was also safe in monkeys
with AIDS and no increase in viral replication nor a
further decrease in CD4 T-cells was observed [129].
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Development
of vaccine
candidates
Validation (monkeys)Evaluation (mice)
Capacity building in developing countries for advanced 
(phase II/III) trials 
- safety
- immunogenicity
- efficacy
- safety
- immunogenicity Human trials
Regulatory 
approval
Cross-sectional/longitudinal studies in natural infection for 
correlates of protection and parameters of trial monitoring 
Fig. 1. HIV Tat vaccine development. Shown are the sequential and integrated activities for the development of the HIV-1 Tat
vaccine programme from the basic research to clinical testing, including parallel activities directed at investigating the correlates
of protection in natural infection and at validating laboratory testing for trial monitoring, and capacity building in developing
countries for advanced clinical testing.
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On the basis of these data, the active Tat protein was
chosen for the conduct of preventive and therapeutic
phase I clinical trials (Fig. 2).
Lesson learned
To guarantee translation to the clinical level, all preclinical
activitiesmustbeconducted incompliancewithregulations
and procedures ensuring safety and data quality. For
example, a processofproductioncompliantwith regulatory
guidelines for human use should be adopted early in the
developmental pipeline. Specific training programmes
should be implemented to support scientists in this task.
Regulatory approval by the national
agency within the European Union
In order to proceed to phase I clinical trials of a new
vaccine in Italy, an application must be submitted to the
Committee for the Evaluation of the Safety and Quality
of New Drugs at Istituto Superiore di Sanita` (ISS) and to
the Italian Ministry of Health (Fig. 5). The process is
regulated by guidelines and laws issued by European and
Italian regulatory authorities (Table 5). Therefore, a
dossier termed ‘Expert Report’ containing the required
information on the quality, safety, immunogenicity and
efficacy of the Tat vaccine and the clinical protocols was
submitted to this Committee, which approved the use of
the Tat vaccine candidate in both healthy and HIV-
infected individuals (Fig. 2). After that, all the relevant
documentation (clinical protocols, psychosocial protocol,
investigator brochure, informed consent, clinical sites,
insurance policy) (Table 6) was submitted and approved
by the central (ISS) and local Ethics Committees/
Institutional Review Boards (Fig. 5). Competitive
enrollment was then started in each clinical site for the
conduct of both the preventive and therapeutic phase I
trials (Fig. 2).
Lesson learned
Approaching regulatory issues represents a fundamental
step in building up translational research programmes,
and requires a specific expertise while being extremely
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2004 2005 200620032002200120001999199819971996
Basic studies on Tat biological properties
Studies on the anti-Tat immune response in natural infection
Preclinical studies on the Tat vaccine (safety, immunogenicity, efficacy)
Preparation of the platforms
GMP development and production
Expert report preparation, submission and approval for human use
Phase I preventive and therapeutic trials and follow-up
Feasibility studies in South Africa
Feasibility studies in Swaziland
Preclinical studies on novel vaccine candidates and formulations
Submission and approval by central and local EC
CRO activities
CAB activities
Fig. 2. Timeline of the Tat vaccine programme. Timeline of the activities undertaken for the development and conduct of phase I
clinical trials with the Tat vaccine candidate, preparatory studies in developing countries and the development of a second/third
generation of Tat-based vaccine candidates. CAB, Community advisory board; CRO, contract research organization; EC, ethical
committee; GMP, good manufacturing practice.
Table 3. Physicochemical, immunochemical and biological
characterization of the Tat protein.
Specifications Tests
Physicochemical
properties and purity
Sodium dodecylsulphate–
polyacrylamide gel
electrophoresis
Comassie blue staining
Silver staining
High-pressure liquid
chromatography
Endotoxin determination
by LAL test
Immunochemical properties Western blot
Biological activity Rescue of Tat-defective
provirus
Uptake by dendritic cells
LAL, Limulus amoebocyte lysate.
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time-consuming and frustrating also because no aca-
demic training in this matter exists. Therefore, training
should be implemented to support scientists in this
task. The implementation of training will help in
properly planning timelines and organizing human and
economic resources.
Good manufacturing practice Tat vaccine
production for phase I studies
Good manufacturing practice-grade process
development of the Tat protein
For the good manufacturing practice (GMP) pro-
duction of the Tat vaccine it was necessary to identify a
validated facility adequate to sustain phase I trials,
which, however, was not available in Italy. A contractor
was finally identified in the United Kingdom, which
produced and released the Tat vaccine according to
current regulations.
The recombinant Tat protein was produced and purified
by diethylaminoethyl and heparin sepharose chroma-
tography, formulated in a suitable buffer in the presence
of human serum albumin and vialed (Fig. 6). Compar-
ability studies with the research-grade product con-
firmed that release specifications remained unchanged
(Table 3). Amino acid terminal sequence and mass
spectrometry were also performed on the GMP
product. Stability tests confirmed that the vialed clinical
lot retained full biological activity for up to 2 years at
808C.
Lesson learned
The need to find a contractor outside Italy was extremely
costly and time consuming, underlining the necessity of a
dedicated small-scale GMP facility in Italy. Thanks to the
support of ISS and of the University of Urbino such a
facility (AVITECH) has been built in Italy for Tat vaccine
production following clinical trials.
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Fig. 3. Physicochemical characterization of the Tat protein vaccine. Shown are the Comassie blue and silver staining as well as
Western blot of the Tat protein separated by sodium dodecylsulphate–polyacrylamide gel electrophoresis. The lower panel
shows the results of high-pressure liquid chromatography (HPLC) of the Tat formulated with bovine serum albumin. This product
was used for in-vitro and preclinical studies.
Fig. 4. Tat uptake by monocyte-derived dendritic cells.
Monocyte-derived dendritic cells were incubated with serial
concentrations (0.1–1000 ng/ml) of the native Tat protein,
medium, or reconstitution buffer for 10 min. The intracyto-
plasmatic Tat content was evaluated by flow cytometry after
staining with specific affinity purified rabbit anti-Tat polyclo-
nal antibodies (or isotype control), followed by secondary
fluorescein-isothiocyanate-conjugated anti-rabbit antibodies
[119]. The percentages of positive cells (compared with
isotype-stained samples) are reported. The bars indicate the
standard deviation. Data are the mean of 86 experiments
performed with cells from 71 different donors and eight
different lots of the Tat protein.
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Table 4. Summary of the immunological responses and post-challenge fate of Tat-vaccinated and control monkeys.
Groupa Monkey
Pre-challenge
Ab titresb
Tatc
neutralization
Proliferatived
response CTLe
Tat-inducedf
TNF-a
Infectiong after
challenge
CD4h T-cell
decline
Tat in 54844 þþ þ þ þ þ – –
RIBI (sc) 54876 þþ þþ þ ND þ – –
54963 þþ þþ þþ – ND þ þ
Tat in 54899 þþþ þþþ þþ þ þ – –
Alum (sc) 55396 þþþ þþþ þ – – þ þ
55240 þþþ þþþ þ þ þ – –
Tat (id) 54222  ND – þ þ – –
Control RIBI 55123 – ND – – – þ þ
Control alum 55129 – ND – – – þ þ
Naive 2 – ND ND ND ND þ þ
Naive 12 – ND ND ND ND þ þ
ND, Not done.
aMonkeys were immunized subcutaneously with Tat (10mg) and the RIBI or aluminum phosphate (alum) adjuvant. One monkey, was immunized
intradermally with Tat (6mg) in the absence of adjuvant.
bAntibody titres to Tat were expressed as the reciprocal of the last positive dilution: –, <10; , 100; þ, >100 3200; þþ, >3200 12 800;
þþþ, >12 800.
cNeutralization of Tat activity on HIV replication by the rescue assay.
dLymphoproliferative response was determined by a standard 3H-thymidine incorporation assay. Stimulation index: –, SI<3;þ, SI3<10;þþ,
SI 10.
eAnti-Tat cytotoxic T-lymphocyte (CTL) activity at 50 : 1 and 25 : 1 effector: target ratio at weeks 28 and 36 after immunization. Values greater than
10% were considered positive.
fTumor necrosis factor alpha (TNF-a) production by peripheral blood mononuclear cells by enzyme-linked immunosorbent assay. Values below
cutoff (15.6 pg/ml) were scored negative.
gAll monkeys were challenged intravenously with 10 MID50 of cynos-derived SHIV89.6Pcy243. Monkeys 2 and 12 were challenged with 28 and
2.8 MID50, respectively. Infection was determined by measuring plasma viraemia and the proviral copy number.
hCD4-cell number was evaluated on citrated blood by a fluorescence-activated cell sorter. The decrease in the absolute number of CD4 T-cells
was defined as >50%. For all methodologies see Cafaro et al. [124] and Maggiorella et al. [128].
EXPERT REPORT: APPLICATION FOR NEW ACTIVE 
SUBSTANCE EVALUATION
- Documentation for the assessment of composition
- Documentation for the assessment of safety
- Clinical protocols
COMMITTEE FOR THE EVALUATION OF 
SAFETY AND QUALITY OF NEW DRUGS
Approval for human use
Identification of the experts committee
CENTRAL AND LOCAL ETHICS COMMITTEES
CLINICAL TRIAL INITIATION
VACCINE PRODUCTION
- Good manufacturing practice 
certification
- Description of the process of production
- Description of physico-chemical
specification of the active substance 
(identity, purity, sterility, biological 
activity)
ITALIAN REGULATION 
EUROPEAN REGULATION
Guidelines for the evaluation of 
composition and safety of new 
active substances 
PRECLINICAL STUDIES AND 
CLINICAL PLAN
- Documentation on toxicology
- Documentation  on pharmachology
- Clinical protocols
Fig. 5. Procedures for approval of the Tat vaccine candidate for human use by regulatory agencies. Reported are the main
documentations and procedures required by the Italian regulatory authorities for approval for human use of the Tat vaccine. See
text for explanation.
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Establishment of clinical, laboratory and
social–behavioural platforms
In order to ensure comparable read-outs for clinical trials
conducted in a multicentre context, all clinical and
laboratory activities, as well as psychosocial and beha-
vioural assessments, were harmonized among the
participants along common good clinical practice
procedures by establishing specific and integrated plat-
forms (Fig. 2 and Fig. 7).
Clinical platform
Parallel preventive and therapeutic phase I clinical trials
were conducted in three sites in Rome (L. Spallanzani
Hospital, San Gallicano Hospital and University of Rome
‘La Sapienza’), and in one site in Milan (S. Raffaele
Hospital; Fig. 8). Clinical activities and responsibilities,
financial support from the sponsor, property of data and
biological samples and confidentiality were regulated by
specific contracts between the sponsor and the clinical
sites. Standard operating procedures were implemented in
the clinical sites to standardize all activities encompassing
prescreening, enrollment and monitoring of the volun-
teers (clinical evaluation, safety laboratory testing, risk
Preventive and therapeutic Tat vaccine trials Ensoli et al. 2251
Table 5. Major European guidelines for the preparation and conduct
of phase I clinical trials of vaccines based on recombinant proteins.
Title Emanating authority
Note for guidance on comparability of
medicinal products containing
biotechnology-derived proteins as
active substance
CPMP/EMEA
Note for preclinical safety evaluation
of biotechnology-derived products
CPMP/EMEA
Note for guidance on safety
pharmacology studies for human
pharmaceuticals
CPMP/EMEA
Note for guidance on repeated dose
toxicity
CPMP/EMEA
Note for guidance on pharmacological
and toxicological testing of vaccines
CPMP/EMEA
Note for guidance on good clinical
practice
CPMP/ICH
Note for guidance on general
consideration for clinical trials
CPMP/ICH
Note for guidance on clinical
evaluation of new vaccines
CPMP/EMEA
Principles and guidelines of good
manufacturing practice in respect of
medicinal products for human use
and investigational products for
human use, 8 October 2003
European Parliament
Community procedures for the
authorization and supervision of
medicinal products for human and
veterinarian use and establishing a
European Medicine Agency,
31 March 2004
European Parliament
Assessment of composition and safety
of new drugs before clinical testing
in humans. Law of decree,
26 April 2002
ISS
Objectives and analysis of the preclinical
studies required to conduct phase I
clinical trials
ISS
Rules for simplification of the procedures
for testing and controlling the new
systems and experimental therapeutic
protocols
Law of decree, 19 December 2001 President of the
Italian Republic
CPMP, Committee for Proprietary Medicinal Products; EMEA,
European Agency for the Evaluation of Medicinal Products; ICH,
International Conference on Harmonization; ISS, Istituto Superiore
di Sanita`.
Table 6. Major guidelines for the activity of the central ethics
committee.
Title Emanating authority
Declaration of Helsinki WMA
Convention for the protection of human
rights and dignity of the human being
with regard to the application of
biology and medicine: Convention on
Human Rights and Biomedicine
(Convention of Oviedo)
Council of Europe
International ethical guidelines for
biomedical research involving human
subjects
CIOMS/WHO
CIOMS, Council for International Organizations of Medical Sciences;
WMA, World Medical Association; WHO, World Health
Organization.
Fig. 6. Vial of the clinical lot of the Tat vaccine candidate
used in the clinical trials.
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assessment, and counseling on risk reduction and on
avoiding pregnancy). Clinical sites were also responsible
for adverse event reporting. In this regard, an independent
Committee for the Evaluation of Adverse Events,
composed of external clinical experts, was appointed
by the sponsor. This committee held periodic meetings
during the study, and submitted interim and final safety
reports to the regulatory authorities.
Laboratory platform
A dedicated Core Laboratory for Immunology and
Virology was created at the San Gallicano Hospital in
Rome as a joint unit with ISS (Fig. 8), and validated
upon an international standard of quality (ISO 9001).
Immunomonitoring was performed by a two-step
strategy with a first line of testing, assessing the strength
and breadth of Tat-specific B- and T-cell responses
(antibody detection and mapping by enzyme-linked
immunosorbent assay, Tat-specific peripheral blood
mononuclear cell proliferation and g-IFN and IL-4
production), and a second line of testing focusing at
multiparametric antigen-specific profiles (proliferation
coupled with an assessment of T helper types 1/2
cytokine production, multiplexed enzyme-linked immu-
nosorbent assay for cytokines and chemokines and
protein microarray), directed at validating novel meth-
odologies for future clinical testing.
Psychological and behavioural platform
Participation in HIV vaccine clinical trials involves
intimate matters, repeated HIV testing and exposure to
scientific and medical concepts that may cause anxiety,
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CONDUCTION OF PHASE I CLINICAL TRIALS
CLINICAL PLATFORM
•  Clinical sites
•  Adverse events
    monitoring committee
LABORATORY
PLATFORM
•  Core lab of
   immunology
   and virology
COMMUNICATION and 
PSYCHOLOGICAL
SOCIO-BEHAVIOURAL
PLATFORM
•  AIDS help line
•  Consulting psychiatry
CONTRACT RESEARCH ORGANIZATION
COMMUNITY ADVISORY BOARD
Fig. 7. Organization of the activities for trial conduct of the Tat vaccine candidate. Activities were organized according to
specific platforms with the support of the contract research organization and the community advisory board.
Fig. 8. Operative structure for the conduct of the preventive and therapeutic phase I trials. Indicated in the figure are the main
institutions and bodies involved in the operative structure for the conduct of the parallel preventive and therapeutic trials with the
Tat vaccine candidate. CAB, Community advisory board; ISS, Istituto Superiore di Sanita`.
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stress and depression, and may also contribute to
dropouts. A specific platform integrating experts from
the clinical sites was therefore created (Fig. 8), and a
psychosocial protocol was implemented for the assess-
ment of psychological and sociobehavioural parameters
to support volunteers throughout critical points during
the study (enrollment, conclusion of the study, follow-up,
screening failure or adverse events).
Communication and enrollment
Information from the sponsor/investigators must provide
a good understanding of the nature of the trial to enable
potential volunteers to weigh accurately the risks and
the benefits of trial participation. To this goal a specific
enrollment procedure was developed. In particular, ISS
announced the starting of the enrollment with a press
release, which referred to the AIDS Helpline at ISS for
both general information on AIDS, vaccine clinical trials
and specific information on Tat vaccine trial participation
(Fig. 9). The AIDS Helpline operators gave to individuals
willing to participate in the trial a dedicated telephone
number for each clinical site, which was chosen by the
volunteers, and an alpha-numeric code needed for the
first visit appointment (Fig. 9).
Contract research organization
To guarantee the quality control and quality assurance of
the clinical trials, a contract research organization was
hired to provide the following services: study preparation
(preparation of case report forms, submission to ethical
committee, investigator qualification visits, generation
and distribution of randomization codes), study initiation
(study-specific monitoring visits, site initiation visits),
study monitoring (routine monitoring visits, drug
accountability and drug returns for destruction, resol-
ution of queries with sites, termination visits), quality
assurance (clinical site audit, database audit), data
management (database design and testing, data transfer,
data entry, validation and query resolution, quality
control of database), analysis and reporting (statistical
analysis plan design, statistical programming, statistical
analysis, International Conference on Harmonization
good clinical practice compliant preparation of clinical
and statistical reports (Fig. 2).
Community advisory board
A community advisory board (CAB) comprising the most
representative Italian non-governmental organizations
involved in all issues relating to HIV/AIDS was
established to provide a communication network among
communities, scientists, community care providers and
the sponsor (Fig. 8). The CAB contributed to establishing
the methodology for ethical information, and provided
activity of counseling and communication to the
volunteers. The CAB also cooperated with ISS in
approaching critical situations such as confidentiality
issues with trial participants.
All the activities performed by the different platforms,
contract research organization and CAB were imple-
mented and coordinated by the sponsor via numerous ad
hoc meetings conducted before and during the trials.
Lesson learned
For the conduct of preventive and therapeutic phase I
studies, a network was created as a highly motivated team.
Networking greatly helped the process of the harmoniza-
tion of procedures and allowed an important ‘exchange’
of expertise among the different platforms, to the full
benefit of the volunteers. In particular, the psychological
platform and the CAB represented a major support to the
volunteers’ wellbeing.
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Fig. 9. Communication and enrollment procedures established for the conduct of trials with the Tat vaccine candidate. Reported
is the algorithm developed to support the communication, recruitment and enrollment for the conduct of phase I clinical trials. See
text for explanations. ISS, Istituto Superiore di Sanita`.
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Parallel preventive and therapeutic phase I
trial conduct
Clinical trials were conducted in healthy HIV-uninfected
adults at low risk of infection (preventive protocol) and in
HIV-1-infected adult asymptomatic volunteers not in
therapy (i.e. CD4 T-cell counts  400 cells/ml and viral
loads  50 000 copies/ml; therapeutic protocol). The
endpoints were to qualify the biologically active Tat
protein as safe (primary endpoint) and immunogenic
(secondary endpoint) in both healthy and HIV-infected
individuals for its further evaluation in phase II trials
(Fig. 8).
Both studies were randomized, placebo-controlled, and
double-blinded. Volunteers were randomly assigned to
one of two treatment arms with different routes of
administration and blinded to the dosage group. In arm A,
volunteers received Tat subcutaneously with alum at a
dose of 7.5, 15 or 30mg, at weeks 0, 4, 8, 12, and 16. One
group of volunteers received alum plus saline solution as
placebo. In arm B, volunteers received Tat intradermally
without adjuvant at a dose of 7.5, 15 or 30mg at weeks 0,
4, 8, 12, and 16; one group of volunteers received saline
solution as placebo.
The study structure is described in Table 7 and all
clinical, laboratory and psychological and sociobeha-
vioural evaluations performed during the trial are
shown in Table 8 and Table 9. Evaluations were
conducted during the treatment phase, the 6-month
follow-up and are continuing for an additional 3 years.
An assessment of clinical and laboratory safety was
performed at several timepoints during the study and
was monitored by the Committee for the Evaluation of
Adverse Events.
The studies have been successfully completed. Both
primary and secondary endpoints were fully achieved
for both the preventive and the therapeutic trials
(manuscripts in preparation), sustaining the advancement
of the Tat vaccine candidate to phase IIA trials both in
Italy and South Africa. On the basis of the results obtained
in phase IIA, an extended ‘proof-of-concept’ phase IIB
trial will be conducted in South Africa (preventive
protocol) and in Italy (therapeutic protocol) for a
preliminary evaluation of efficacy (Fig. 10).
Lesson learned
The volunteers have established close relationships
between themselves during the trial, providing an
additional level of care and support. Their participation
was so enthusiastic that it was proposed to the sponsor that a
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Table 7. Clinical protocols of the Tat vaccine candidate: study
structure.
Activity Description Schedule
Prescreening 2 Visits Weeks 4
and 1
Treatment phase 5 Immunizations Weeks 0, 4, 8,
12, 16
5 Visits, 24 h after
each immunization
Weeks 0, 4, 8,
12, 16
5 Visits, 7 days after
each immunization
Weeks 1, 5, 9,
13, 17
1 Visit, end of treatment
phase
Week 24
Follow-up 1 Visit (ISS P-001) Week 48
2 Visits (ISS T-001) Weeks 36, 48
Additional follow-up 2 Visits (ISS P-001) Weeks 96, 144
4 Visits (ISS T-001) Weeks 72, 96,
120, 144
Interim analysis First database locking Week 24
Final analysis Second database locking Week 48
Reported are the key trial activities and their time schedule according
to the clinical protocols designed for both the preventive (ISS P-001)
and the therapeutic (ISS T-001) trials with the Tat vaccine candidate.
Table 8. Clinical and laboratory evaluations performed in the
preventive and therapeutic clinical trials of the Tat vaccine
candidate.
Clinical evaluation Physical and clinical history
12-lead electrocardiogram
Psychological assessment
Behavioural assessment
Quality of life assessment
Risk assessment
Risk reduction counselling
Counselling on avoiding
pregnancy
Laboratory safety evaluation Haematology
Coagulation assessment
Blood chemistry
CD4 T-cell count
Urine dipstick
HIV-1 plasma viraemiaa
Immunological evaluation Anti-Tat IgM, IgG and IgA
antibodies
Lymphoproliferative response
to Tat
g-IFN and IL-4 production in
response to Tat (Elispot)
Lymphocyte phenotyping
Human leukocyte antigen typing
aHIV-1 plasma viraemia was included as a safety parameter only for
the therapeutic protocol.
Table 9. Main objectives and activities of the psychosocial protocol.
Support the clinical trial design and conduct:
Contribute to the application of the inclusion/exclusion criteria
indicated in the clinical protocol (identification of psychotic
disorders, depression, suicidal tendency)
Identify psychological profiles indicating the need for more
accurate support during the most critical steps of the trial
(enrollment, occurrence of adverse events, drop-out,
conclusion of the study), to prevent drop-out and risk behaviour
Evaluate psychosocial and behavioural parameters of the
volunteers:
Assess the psychological impact of participation in the trial, with
particular attention to potential anxiety symptoms
Evaluate motivation, expectations and informational needs
regarding the vaccination protocol with particular attention to
the prevention of potential risk behaviour
Evaluate the quality of life of the participants at enrollment and
during the study
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working group should be created to share their experience
with the volunteers of the following clinical trials.
Of note is the fact that this is the first time that the same
vaccine product has been tested in parallel in preventive
and therapeutic trials, allowing a comparison of the safety
and immunogenicity in two different populations. In
particular, trials in infected subjects may give key
information on the impact of vaccination on HIV
infection and pathogenesis and a fast readout on vaccine
efficacy, providing insights for the development of a
non-sterilizing vaccine.
Preparatory studies in Africa for the
conduct of advanced clinical trials
Strengthening and building up the local clinical and
laboratory capacity as well as community involvement are
crucial steps that must be undertaken before starting
clinical testing in African countries. Preparatory studies
are also essential to estimate HIV incidence and
prevalence in the populations targeted by vaccination,
and to evaluate the immune cross-recognition of the
vaccine antigen. To this goal, preparatory studies are
ongoing in Africa (Fig. 2). In particular, cooperation with
South Africa has been established with the HIV/AIDS
Vaccine Division at the Perinatal HIV Research Unit at
the Chris Hani Baragwanath Hospital in Soweto
(Johannesburg, South Africa) within bilateral as well as
European Union-funded vaccine programmes. A similar
platform is being established in Swaziland.
Lessons learned
Feasibility studies for the advanced clinical testing of a
vaccine in developing countries have to be started well in
advance, because a number of issues must be resolved
before starting clinical trials. Priority issues are:
(i) evaluating the willingness of both local political and
scientific authorities, as well as key stakeholders of the
community to host vaccine trials; (ii) building up
laboratory and clinical capacity and identifying suitable
cohorts for vaccine testing; and (iii) performing back-
ground immunological and virological field studies.
Sponsorship of Tat vaccine clinical
development
The ISS is a governmental agency with functions of the
Centers forDiseaseControl andPrevention,NationalFood
and Drug Administration and National Institutes of Health.
As such, the ISS is strongly involved in basic and applied
research in areas that represent a threat to national health,
including HIV/AIDS. On the basis of the promising results
from preclinical studies with the Tat vaccine, the ISS has
sponsored, through the allocation of specific funds,
preventive and therapeutic phase I clinical trials of the
Tat vaccine. These trials represent the first public, fully
government-supported phase I trials of a vaccine against
HIV/AIDS in Italy. On the basis of the data obtained, the
Italiangovernmenthascommitted to fundphase IIAandIIB
preventive and therapeutic trials in Italy and South Africa.
Full sponsorship by a government agency such as the
ISS represents a guarantee of the no-profit nature of
the programme, while providing protection of the
intellectual properties of the Tat vaccine.
Lesson learned
Institutional sponsorship of the Italian vaccine pro-
gramme was very favourably perceived by all players,
including volunteers, non-governmental organizations
and developing countries. At the same time, both the
protection of intellectual properties as well as the
advancement to phase IIB trials with public resources
greatly reduce the financial risk of the private enterprises
willing to develop the vaccine further.
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Fig. 10. Timeline of the clinical development of the Tat vaccine candidate. Reported is the timeline of the ongoing and future
clinical testing of the Tat vaccine candidate in Italy and African countries for both the preventive and therapeutic approaches.
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National and international HIV/AIDS
vaccine networks
The National AIDS Centre at ISS has established
networks with national and international public and
private institutions focused on the development of new
preventive and therapeutic vaccine strategies to curb the
HIV-1 pandemic. Among them is the AIDS Vaccine
Integrated Project (AVIP; http://avip-eu.org), which is
a European Union-funded 5-year project involving
16 institutions from the public and private sectors from
Italy, Sweden, France, Germany, Finland, United
Kingdom and South Africa. The design of HIV vaccines
within AVIP (Table 10) is based on two general ideas.
One is a ‘minimalistic’ approach combining regulatory
HIV proteins (Tat or Nef) with a modified (V2 deleted)
Env (DV2 Env). The other approach aims at ‘imitating’ a
live attenuated vaccine using as many HIV genes as
necessary (‘maximalistic’ approach). The specific
objective and activities of AVIP are described in
Table 11 [130].
The Italian Concerted Action on HIV/AIDS Vaccine
Development (ICAV) has been established under the
National AIDS Programme coordinated by the National
AIDS Centre and consists of a network of approximately
70 Italian centres. The activities of the ICAV programme
are described in Table 12.
Through these and the other networks in which ISS
participates, several vaccines and formulations by
different participants are in the pipeline. These novel
vaccine candidates also include second-generation Tat-
based vaccines such as the Tat/DV2Env combination
[AVIP, Mucosal vaccines for poverty-related diseases
(MUVAPRED), very innovative AIDS vaccine (VIAV)
and ISS/Novartis–Chiron agreement] and Tat alone
or in combination with other HIV products delivered
by micro/nanoparticles (ICAV) as well as herpesvirus
vectors (ICAV) and replication-competent adenovirus
vectors (Italy–USA, ISS/National Cancer Institute–
National Institutes of Health) for parenteral and mucosal
vaccination strategies.
Lesson learned
The establishment of national and international networks,
including private companies, public and academic
institutions, is essential for vaccine development and
should always include training programmes such as the
AVIP International School (www.avip-eu.com), which is
proving to be an optimal forum to train students, scientists
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Table 10. Vaccine candidates to be tested in phase I trials within the
AIDS Vaccine Integrated Project consortium.
Vaccine antigens Clade
Tat Env (V2-deleted) B, C
Nef Env (V2-deleted) B, C
Multi-HIV antigens/epitopesa A, B, C, FGH
HIV multigene (Nef, Rev, Tat, Gag, RT, Env) A, B, C
aMulti-HIV A, B, C, or FGH clade antigens and epitopes including
full-length Rev, Tat, Nef, Gag (p17, p24) antigens and other antigens
and more than 20 T-cell epitopes from Pol, Protease, Env antigens.
Vaccine candidates are represented by four combined vaccines,
which are composed of individual vaccine antigens already tested
in phase I studies, or under clinical testing. Candidate vaccines will
undergo trials after preclinical testing aimed at selecting the optimal
formulation and immunization protocol of the antigen combination.
Table 11. Scientific structure of the AIDS Vaccine Integrated
Project.
Work packages
1 Preclinical studies (mice, monkeys) to select the best formulation
and vaccination protocol of AVIP vaccine candidates
for phase I studies
2 Good manufacturing practice production/toxicology, dossier
preparation and regulation (approval for human use)
3 Preventive phase I trials and follow-up
4 Therapeutic phase I trial and follow-up
5 Immunological field preparatory studies focused on cross-clade
immune recognition of AVIP vaccine antigens for future
phase II/III trials in developing countries
6 European Vaccine against AIDS programme to support all
research activities
7 Coordination of science, training, business and administrative
management
Reported are the key activities of the AIDS Vaccine Integrated Project
(AVIP), which are organized in work packages, each performed by a
dedicated team of scientists.
Table 12. Scientific structure of the Italian Concerted Action on the
development of a Vaccine against HIV/AIDS.
Work packages
1 In-vitro analysis of the effects of HIV regulatory proteins and
candidate vaccines on immune cells
2 Natural and adaptive immune responses against candidate
vaccine antigens in natural and experimental models of
protection relevant to vaccine development
3 Vaccine development and selection (safety and immunogenicity
in animal models)
4 Animal models for efficacy studies and validation of
vaccine candidates
5 Development and production of research grade antigens and
establishment of standard operating procedures for good
manufacturing practice production of candidate vaccines
6 Preparatory studies (laboratory and clinical setting) for
preventive and therapeutic clinical trials in adults
7 Evaluation of correlates of protection in paediatric cohorts for
the implementation of therapeutic and preventive HIV-1
vaccine strategies
8 Epidemiological, virological and cross-clade immunological
field studies for phase II/III vaccine trials in developing
countries
9 Behavioural and psychosocial aspects of the HIV-1 infection
related to vaccine trials
10 Development and standardization of techniques and diagnostic
assays and preparation of standard operating procedures for
vaccine testing in animal models and humans
11 Coordination of science, training, business and administrative
management
Reported are the key activities of the Italian Concerted Action on the
development of a Vaccine against HIV/AIDS (ICAV) programme,
which are organized in work packages, each performed by a
dedicated team of scientists.
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and clinicians in the difficult aspects of HIV/AIDS vaccine
development. Although creating these networks has been a
very challenging task, particularly for management, the
intellectual, scientific, and human interactions among the
participants have generated true cooperative teams adding a
synergistic value to research conduct.
In conclusion, the development of the Tat vaccine
programme required a multidisciplinary approach, ade-
quate economic resources, training and a great effort of
managing and coordination. The programme has been
fully funded and conducted by the ISS, which is the Italian
health governmental agency. A great effort was, therefore,
dedicated to build up a structure capable of translational
research. The accomplishment of this task took 10 years
and taught us important lessons (Table 13), at the same time
resulting in key achievements. This structure is now ready
to run the following clinical phases of the Tat vaccine, as
well as new vaccine programmes. In addition, such
organization offers the flexibility to update all the different
areas of the programme rapidly in response to scientific
needs and innovation, with no interference from private/
profit interests or ‘fashioned’ scientific agendas, which
have undermined targeting regulatory genes as well as
conducting therapeutic vaccine trials that may offer new
opportunities in HIV treatment. In particular, the parallel
conduct of preventive and therapeutic trials with the Tat
vaccine candidate has provided important insights into
HIV pathogenesis and for the development of a preventive
vaccine based on virus control and not on sterilizing
immunity. Finally, the creation of networks for vaccine
development is greatly helping in this task and provides a
suitable forum for training programmes, which are greatly
needed in the field.
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Table 13. Problems, solutions and lessons learned during the development of the Tat vaccine.
Problems Solutions and lessons learned
Identification of a new vaccine target Solution: Tat was chosen based on its role in HIV pathogenesis and on the protective role of the
anti-Tat immune response in natural infection.
Lesson: Integrate studies of pathogenesis and immune response in natural infection in antigen
selection and vaccine design.
Selection of the best Tat immunogen Solution: Biologically active Tat protein was chosen for its properties (dendritic cell targeting,
adjuvanticity) and easier regulatory issues.
Lesson: Subunit vaccines should not be dismissed. Selection depends upon the properties of the
antigen.
Guidelines issued by regulatory
authorities heavily impact
Solution: Continuous cross-talk with regulatory experts.
production strategies
Lesson: Adopt compliant approaches as early as possible in the vaccine pipeline. Implement
training programmes on regulatory issues to support clinical development.
Paucity of good manufacturing
practice facilities for early clinical
Solution: A dedicated good manufacturing practice facility.
testing
Lesson: Public sponsorship/contribution to create good manufacturing practice facilities dedicated
to translational research.
Harmonization of procedures in the
context of a multicentric conduct
Solution: Early establishment of integrated platforms harmonizing the different activities.
of clinical trials
Lesson: Bring together highly motivated players acting as a team and implement training.
Stress in volunteers induced by trial
participation
Solution: Psychological support of the volunteers from the screening phase and throughout
the trial.
Lesson: A psychosocial–behavioural platform strongly contributes to volunteers’ wellbeing and
trial retention.
To advance vaccine clinical testing in
developing countries
Solution: Early cooperation with local scientists and authorities for capacity building, feasibility
studies and training.
Lesson: Obtain from political authorities, scientific institutions and communities an early
commitment.
Funding of vaccine development up
to clinical testing
Solution: Government sponsorship up to phase IIB – proof of concept of efficacy.
Lesson: Sensitize and involve key public and governmental bodies on AIDS and vaccine as the
solution to stop the epidemic (show cost/benefits for public health and advancing research in
general).
Need for scientific exchange Solution: Creation of cooperative networks capable of providing key scientific inputs.
Lesson: Scientific networking is crucial to build up translational research programmes.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
G. Tambussi, R. Visintini (S. Raffaele Hospital, Milan);
P. Narciso, A. Antinori, G. D’Offizi, M. Giulianelli
(L. Spallanzani Hospital, Rome); A. Di Carlo, G. Palamara,
M. Giuliani (S. Gallicano Hospital); M. Carta (University
of Rome ‘La Sapienza’); the Adverse Events Monitoring
Committee: P. Popoli (Istituto Superiore di Sanita`); M.
Galli (L. Sacco Hospital, Milan); M. Picardo (San Gallicano
Hospital, Rome); and C.F. Perno (University of Rome
‘Tor Vergata’); the Community Advisory Board: R.
Iardino (NPS); S. Marcotullio (I-CAB); A. Vatrella (LILA);
C. Valvo (GITA); G. Bevacqua (Positifs Onlus); S.
Lombardo (M. Mieli); R. Gavioli and P. Marconi
(University of Ferrara); S. Barnett (Novartis, Emeryville,
USA); M. Robert-Guroff (NCI–NIH, Bethesda, USA);
E. Vardas (University of the Witwatersrand, Soweto, South
Africa); F.M. Regini and P. Sergiampietri for technical
and secretarial support and A. Carinci and S. Ceccarelli
for editorial assistance. A particular thanks to all trial
volunteers.
Sponsorship: This work was funded by Istituto Super-
iore di Sanita` special funding for Tat vaccine trials, the
Italian Concerted Action on HIV-AIDS Vaccine Devel-
opment (ICAV; National AIDS Programme), the AIDS
Vaccine Integrated Project (AVIP; European Commis-
sion, grant LSHP-CT-2004-503487), and the Italian
Ministry of Health and Foreign Affairs.
References
1. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce
protective antibodies. Nat Rev Immunol 2004; 4:199–210.
2. Humbert M, Dietrich U. The role of neutralizing antibodies in
HIV infection. AIDS Rev 2006; 8:51–59.
3. Srivastava IK, Ulmer JB, Barnett SW. Neutralizing anti-
body responses to HIV: role in protective immunity and
challenges for vaccine design. Expert Rev Vaccines 2004;
3 (4 Suppl.):S33–S52.
4. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD,
Moore JP, et al. HIV vaccine design and the neutralizing
antibody problem. Nat Immunol 2004; 5:233–236.
5. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC,
Hahn B, et al. Public health. A sound rationale needed for
phase III HIV-1 vaccine trials. Science 2004; 303:316.
6. McNeil JG, Johnston MI, Birx DL, Tramont EC. Policy rebuttal
HIV vaccine trial justified. Science 2004; 303:961.
7. Trinvuthipong C. Thailand’s prime-boost HIV vaccine phase
III. Science 2004; 303:954–955.
8. Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas
ML, et al. Support for the RV144 HIV vaccine trial. Science
2004; 305:177–180.
9. Slobod KS, Bonsignori M, Brown SA, Zhan X, Stambas J,
Hurwitz JL. HIV vaccines: brief review and discussion of
future directions. Expert Rev Vaccines 2005; 4:305–
313.
10. Graham BS, Mascola JR. Lessons from failure–preparing for
future HIV-1 vaccine efficacy trials. J Infect Dis 2005;
191:647–649.
11. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para
MF. Placebo-controlled phase 3 trial of a recombinant gly-
coprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis
2005; 191:654–665.
12. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW,
Montefiori DC, et al. Containment of simian immunodefi-
ciency virus infection in vaccinated macaques: correlation
with the magnitude of virus-specific pre- and postchallenge
CD4R and CD8R T cell responses 2. J Immunol 2002;
169:4778–4787.
13. Okuda K, Bukawa H, Hamajima K, Kawamoto S, Sekigawa K,
Yamada Y, et al. Induction of potent humoral and cell-
mediated immune responses following direct injection of
DNA encoding the HIV type 1 env and rev gene products.
AIDS Res Hum Retroviruses 1995; 11:933–943.
14. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K,
Wang B, et al. In vivo engineering of a cellular immune
response by coadministration of IL-12 expression vector with
a DNA immunogen. J Immunol 1997; 158:816–826.
15. Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z,
Maggiorella MT, et al. Protective efficacy of a multicompo-
nent vector vaccine in cynomolgus monkeys after intrarectal
simian immunodeficiency virus challenge. J Gen Virol 2004;
85:1191–1201.
16. Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C,
Betti M, et al. Immunization with low doses of HIV-1 tat DNA
delivered by novel cationic block copolymers induces CTL
responses against Tat. Vaccine 2003; 21:1103–1111.
17. Caselli E, Betti M, Grossi MP, Balboni PG, Rossi C, Boarini C,
et al. DNA immunization with HIV-1 tat mutated in the trans
activation domain induces humoral and cellular immune
responses against wild-type Tat. J Immunol 1999; 162:
5631–5638.
18. Cui Z, Patel J, Tuzova M, Ray P, Phillips R, Woodward JG, et al.
Strong T cell type-1 immune responses to HIV-1 Tat (1-72)
protein-coated nanoparticles. Vaccine 2004; 22:2631–2640.
19. Marinaro M, Riccomi A, Rappuoli R, Pizza M, Fiorelli V,
Tripiciano A, et al. Mucosal delivery of the human immuno-
deficiency virus-1 Tat protein in mice elicits systemic neu-
tralizing antibodies, cytotoxic T lymphocytes and mucosal
IgA. Vaccine 2003; 21:3972–3981.
20. Morris CB, Thanawastien A, Sullivan DE, Clements JD.
Identification of a peptide capable of inducing an HIV-1
Tat-specific CTL response. Vaccine 2001; 20:12–15.
21. Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM,
Zagury JF, Bizzini B, et al. Safety and immunogenicity of
HIV-1 Tat toxoid in immunocompromised HIV-1-infected
patients. J Hum Virol 1998; 1:293–298.
22. Boykins RA, Ardans JA, Wahl LM, Lal RB, Yamada KM,
Dhawan S. Immunization with a novel HIV-1-Tat multiple-
peptide conjugate induces effective immune response in
mice. Peptides 2000; 21:1839–1847.
23. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G,
et al. Therapeutic vaccination with MVA–HIV-1 nef elicits
Nef-specific T-helper cell responses in chronically HIV-1
infected individuals. Vaccine 2003; 22:21–29.
24. Osterhaus AD, van Baalen CA, Gruters RA, Schutten M,
Siebelink CH, Hulskotte EG, et al. Vaccination with Rev
and Tat against AIDS. Vaccine 1999; 17:2713–2714.
25. Hel Z, Tryniszewska E, Tsai WP, Johnson JM, Harrod R, Fullen
J, et al. Design and in vivo immunogenicity of a polyvalent
vaccine based on SIVmac regulatory genes. DNA Cell Biol
2002; 21:619–626.
26. Hejdeman B, Bostrom AC, Matsuda R, Calarota S, Lenkei R,
Fredriksson EL, et al. DNA immunization with HIV early genes
in HIV type 1-infected patients on highly active antiretroviral
therapy. AIDS Res Hum Retroviruses 2004; 20:860–870.
27. Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers WM,
Ten Haaft PJ, et al. Qualitative T-helper responses to multiple
viral antigens correlate with vaccine-induced immunity to
simian/human immunodeficiency virus infection. J Virol 2004;
78:3333–3342.
28. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM,
Boyson JE, et al. Effective induction of simian immunodefi-
ciency virus-specific cytotoxic T lymphocytes in macaques by
using a multiepitope gene and DNA prime-modified vaccinia
virus Ankara boost vaccination regimen. J Virol 1999; 73:
7524–7532.
29. MwauM,CebereI,Sutton J,ChikotiP,WinstoneN,WeeEG,etal.
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in
clinical trials: stimulation of HIV-specific T-cell responses by
DNA and recombinant modified vaccinia virus Ankara (MVA)
vaccines in humans. J Gen Virol 2004; 85:911–919.
30. Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K,
Morner A, et al. Enhanced cellular immunity and systemic
control of SHIV infection by combined parenteral and mu-
cosal administration of a DNA prime MVA boost vaccine
regimen. J Gen Virol 2004; 85:2407–2419.
2258 AIDS 2006, Vol 20 No 18
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
31. Nilsson C, Makitalo B, Berglund P, Bex F, Liljestrom P,
Sutter G, et al. Enhanced simian immunodeficiency virus-
specific immune responses in macaques induced by priming
with recombinant Semliki Forest virus and boosting with mod-
ified vaccinia virus Ankara. Vaccine 2001; 19:3526–3536.
32. Asakura Y, Hinkula J, Leandersson AC, Fukushima J, Okuda K,
Wahren B. Induction of HIV-1 specific mucosal immune
responses by DNA vaccination. Scand J Immunol 1997;
46:326–330.
33. Dominici S, Laguardia ME, Serafini G, Chiarantini L, Fortini C,
Tripiciano A, et al. Red blood cell-mediated delivery of
recombinant HIV-1 Tat protein in mice induces anti-Tat
neutralizing antibodies and CTL. Vaccine 2003; 21:2073–
2081.
34. Opi S, Peloponese JM Jr, Esquieu D, Watkins J, Campbell G,
De MJ, et al. Full-length HIV-1 Tat protein necessary for a
vaccine. Vaccine 2004; 22:3105–3111.
35. Kim JJ, Yang JS, Nottingham LK, Lee DJ, Lee M, Manson KH,
et al. Protection from immunodeficiency virus challenges in
rhesus macaques by multicomponent DNA immunization.
Virology 2001; 285:204–217.
36. Allen TM, Mortara L, Mothe BR, Liebl M, Jing P, Calore B, et al.
Tat-vaccinated macaques do not control simian immunode-
ficiency virus SIVmac239 replication. J Virol 2002; 76:4108–
4112.
37. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC,
Sandstrom E, et al. Cellular cytotoxic response induced by
DNA vaccination in HIV-1-infected patients. Lancet 1998;
351:1320–1325.
38. Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM,
Weinhold KJ, et al. Immune responses in asymptomatic HIV-
1-infected patients after HIV-DNA immunization followed by
highly active antiretroviral treatment. J Immunol 1999;
163:2330–2338.
39. Malkevitch N, Rohne D, Pinczewski J, Aldrich K,
Kalyanaraman VS, Letvin NL, et al. Evaluation of combination
DNA/replication-competent Ad-SIV recombinant immuni-
zation regimens in rhesus macaques. AIDS Res Hum
Retroviruses 2004; 20:235–244.
40. Ayyavoo V, Kudchodkar S, Ramanathan MP, Le P, Muthumani
K, Megalai NM, et al. Immunogenicity of a novel DNA vaccine
cassette expressing multiple human immunodeficiency virus
(HIV-1) accessory genes. AIDS 2000; 14:1–9.
41. Borsutzky S, Fiorelli V, Ebensen T, Tripiciano A, Rharbaoui F,
Scoglio A, et al. Efficient mucosal delivery of the HIV-1 Tat
protein using the synthetic lipopeptide MALP-2 as adjuvant.
Eur J Immunol 2003; 33:1548–1556.
42. Goldstein G, Manson K, Tribbick G, Smith R. Minimization of
chronic plasma viremia in rhesus macaques immunized with
synthetic HIV-1 Tat peptides and infected with a chimeric
simian/human immunodeficiency virus (SHIV33). Vaccine
2000; 18:2789–2795.
43. Asakura Y, Hamajima K, Fukushima J, Mohri H, Okubo T,
Okuda K. Induction of HIV-1 Nef-specific cytotoxic T lym-
phocytes by Nef-expressing DNA vaccine. Am J Hematol
1996; 53:116–117.
44. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Ayyavoo
V, Zhang D, et al. Inclusion of Vpr accessory gene in a plasmid
vaccine cocktail markedly reduces Nef vaccine effectiveness
in vivo resulting in CD4 cell loss and increased viral loads in
rhesus macaques. J Med Primatol 2002; 31:179–185.
45. Kjerrstrom A, Hinkula J, Engstrom G, Ovod V, Krohn K,
Benthin R, et al. Interactions of single and combined human
immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virol-
ogy 2001; 284:46–61.
46. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A. DNA
multi-CTL epitope vaccines for HIV and Plasmodium
falciparum: immunogenicity in mice. Vaccine 1998; 16:
426–435.
47. Hinkula J, Svanholm C, Schwartz S, Lundholm P, Brytting M,
Engstrom G, et al. Recognition of prominent viral epitopes
induced by immunization with human immunodeficiency
virus type 1 regulatory genes. J Virol 1997; 71:5528–
5539.
48. Hinkula J, Lundholm P, Wahren B. Nucleic acid vaccination
with HIV regulatory genes: a combination of HIV-1 genes in
separate plasmids induces strong immune responses. Vaccine
1997; 15:874–878.
49. Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N,
et al. Construction and immunogenicity in a prime-boost
regimen of a Semliki Forest virus-vectored experimental
HIV clade A vaccine. J Gen Virol 2003; 84:361–368.
50. MacGregor RR, Ginsberg R, Ugen KE, Baine Y, Kang CU,
Tu XM, et al. T-cell responses induced in normal volunteers
immunized with a DNA-based vaccine containing HIV-1 env
and rev. AIDS 2002; 16:2137–2143.
51. Okuda K, Xin KO, Tsuji T, Bukawa H, Tanaka S, Koff WC, et al.
DNA vaccination followed by macromolecular multicompo-
nent peptide vaccination against HIV-1 induces strong anti-
gen-specific immunity. Vaccine 1997; 15:1049–1056.
52. Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka SI,
et al. Cationic liposomes are a strong adjuvant for a DNA
vaccine of human immunodeficiency virus type 1. AIDS Res
Hum Retroviruses 1997; 13:1421–1428.
53. Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L,
Bagarazzi ML, et al. Protection of chimpanzees from high-
dose heterologous HIV-1 challenge by DNA vaccination. Nat
Med 1997; 3:526–532.
54. Gomez-Roman VR, Florese RH, Peng B, Montefiori DC,
Kalyanaraman VS, Venzon D, et al. An adenovirus-
based HIV subtype B prime/boost vaccine regimen elicits
antibodies mediating broad antibody-dependent cellular
cytotoxicity against non-subtype B HIV strains. J Acquir
Immune Defic Syndr 24 August 2006; E-pub ahead of print.
in press.
55. Castaldello A, Brocca-Cofano E, Voltan R, Triulzi C,
Altavilla G, Laus M, et al. DNA prime and protein boost
immunization with innovative polymeric cationic core-shell
nanoparticles elicits broad immune responses and strongly
enhance cellular responses of HIV-1 tat DNA vaccination.
Vaccine 2006; 24:5655–5669.
56. Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC,
Hocker L, et al. Systemic immunization with an ALVAC–HIV-
1/protein boost vaccine strategy protects rhesus macaques
from CD4R T-cell loss and reduces both systemic and mu-
cosal simian–human immunodeficiency virus SHIVKU2 RNA
levels. J Virol 2006; 80:3732–3742.
57. Neumann J, Stitz J, Konig R, Seibold E, Norley S, Flory E, et al.
Retroviral vectors for vaccine development: induction of HIV-
1-specific humoral and cellular immune responses in rhesus
macaques using a novel MLV(HIV-1) pseudotype vector.
J Biotechnol 2006; 124:615–625.
58. Borsutzky S, Ebensen T, Link C, Becker PD, Fiorelli V,
Cafaro A, et al. Efficient systemic and mucosal responses
against the HIV-1 Tat protein by prime/boost vaccination
using the lipopeptide MALP-2 as adjuvant. Vaccine 2006;
24:2049–2056.
59. Patel J, Galey D, Jones J, Ray P, Woodward JG, Nath A, et al.
HIV-1 Tat-coated nanoparticles result in enhanced humoral
immune responses and neutralizing antibodies compared to
alum adjuvant. Vaccine 2006; 24:3564–3573.
60. Amara RR, Smith JM, Staprans SI, Montefiori DC,
Villinger F, Altman JD, et al. Critical role for Env as well as
Gag-Pol in control of a simian–human immunodeficiency
virus 89.6P challenge by a DNA prime/recombinant modified
vaccinia virus Ankara vaccine. J Virol 2002; 76:6138–
6146.
61. Verrier B, Le GR, Taman-Onal Y, Terrat C, Guillon C,
Durand PY, et al. Evaluation in rhesus macaques of Tat and
rev-targeted immunization as a preventive vaccine against
mucosal challenge with SHIV-BX08. DNA Cell Biol 2002;
21:653–658.
62. Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van AG,
Cranage M, et al. Comparison of the efficacy of early versus
late viral proteins in vaccination against SIV. Vaccine 2002;
20:2921–2927.
63. Voss G, Manson K, Montefiori D, Watkins DI, Heeney J,
Wyand M, et al. Prevention of disease induced by a partially
heterologous AIDS virus in rhesus monkeys by using an
adjuvanted multicomponent protein vaccine. J Virol 2003;
77:1049–1058.
64. Patterson LJ, Malkevitch N, Zhao J, Peng B, Robert-Guroff M.
Potent, persistent cellular immune responses elicited by se-
quential immunization of rhesus macaques with Ad5 host
range mutant recombinants encoding SIV Rev and SIV Nef.
DNA Cell Biol 2002; 21:627–635.
Preventive and therapeutic Tat vaccine trials Ensoli et al. 2259
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
65. Amara RR, Villinger F, Altman JD, Lydy SL, O’Neil SP,
Staprans SI, et al. Control of a mucosal challenge and
prevention of AIDS by a multiprotein DNA/MVA vaccine.
Vaccine 2002; 20:1949–1955.
66. Partidos CD, Moreau E, Chaloin O, Tunis M, Briand JP,
Desgranges C, et al. A synthetic HIV-1 Tat protein breaches
the skin barrier and elicits Tat-neutralizing antibodies and
cellular immunity. Eur J Immunol 2004; 34:3723–3731.
67. Dale CJ, De RR, Stratov I, Chea S, Montefiori DC, Thomson S,
et al. Efficacy of DNA and fowlpox virus priming/boosting
vaccines for simian/human immunodeficiency virus. J Virol
2004; 78:13819–13828.
68. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine.
Nat Med 1996; 2:960–964.
69. Gallo RC. Tat as one key to HIV-induced immune pathogenesis
andTat (correction ofPat) toxoid asan important component of
a vaccine. Proc Natl Acad Sci U S A 1999; 96:8324–8326.
70. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R,
Morgan RA, et al. Release, uptake, and effects of extracellular
human immunodeficiency virus type 1 Tat protein on cell
growth and viral transactivation. J Virol 1993; 67:277–287.
71. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator
gene of human T-lymphotropic virus type III (HTLV-III).
Science 1985; 229:69–73.
72. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM,
Reyes G, et al. The trans-activator gene of HTLV-III is essential
for virus replication. Nature 1986; 320:367–371.
73. Peruzzi F. The multiple functions of HIV-1 Tat: proliferation
versus apoptosis. Front Biosci 2006; 11:708–717.
74. Huigen MC, Kamp W, Nottet HS. Multiple effects of HIV-1
trans-activator protein on the pathogenesis of HIV-1 infec-
tion. Eur J Clin Invest 2004; 34:57–66.
75. Wu Y, Marsh JW. Selective transcription and modulation of
resting T cell activity by preintegrated HIV DNA. Science
2001; 293:1503–1506.
76. Chen D, Wang M, Zhou S, Zhou Q. HIV-1 Tat targets micro-
tubules to induce apoptosis, a process promoted by the pro-
apoptotic Bcl-2 relative Bim. EMBO J 2002; 21:6801–6810.
77. Campbell GR, Watkins JD, Esquieu D, Pasquier E, Loret EP,
Spector SA. The C terminus of HIV-1 Tat modulates the extent
of CD178-mediated apoptosis of T cells. J Biol Chem 2005;
280:38376–38382.
78. Bartz SR, Emerman M. Human immunodeficiency virus type 1
Tat induces apoptosis and increases sensitivity to apoptotic
signals by up-regulating FLICE/caspase-8. J Virol 1999;
73:1956–1963.
79. Gibellini D, Re MC, Ponti C, Vitone F, Bon I, Fabbri G, et al.
HIV-1 Tat protein concomitantly down-regulates apical
caspase-10 and up-regulates c-FLIP in lymphoid T cells: a
potential molecular mechanism to escape TRAIL cytotoxicity.
J Cell Physiol 2005; 203:547–556.
80. Yang Y, Tikhonov I, Ruckwardt TJ, Djavani M, Zapata JC,
Pauza CD, et al. Monocytes treated with human immunode-
ficiency virus Tat kill uninfected CD4(R) cells by a tumor
necrosis factor-related apoptosis-induced ligand-mediated
mechanism. J Virol 2003; 77:6700–6708.
81. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J,
Walczak H, et al. Sensitization of T cells to CD95-mediated
apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497–
500.
82. Ott M, Emiliani S, Van LC, Herbein G, Lovett J, Chirmule N,
et al. Immune hyperactivation of HIV-1-infected T cells
mediated by Tat and the CD28 pathway. Science 1997;
275:1481–1485.
83. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, et al. Tat
protein induces self-perpetuating permissivity for productive
HIV-1 infection. Proc Natl Acad Sci U S A 1997; 94:8116–8120.
84. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. Induction
of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.
Science 1995; 268:429–431.
85. McCloskey TW, Ott M, Tribble E, Khan SA, Teichberg S,
Paul MO, et al. Dual role of HIV Tat in regulation of apoptosis
in T cells. J Immunol 1997; 158:1014–1019.
86. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B.
HIV-1 Tat protein exits from cells via a leaderless secretory
pathway and binds to extracellular matrix-associated heparan
sulfate proteoglycans through its basic region. AIDS 1997;
11:1421–1431.
87. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F.
Tat protein of HIV-1 stimulates growth of cells derived from
Kaposi’s sarcoma lesions of AIDS patients. Nature 1990;
345:84–86.
88. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S,
Raffeld M, et al. Synergy between basic fibroblast growth
factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma.
Nature 1994; 371:674–680.
89. Marchio S, Alfano M, Primo L, Gramaglia D, Butini L,
Gennero L, et al. Cell surface-associated Tat modulates HIV-
1 infection and spreading through a specific interaction with
gp120 viral envelope protein. Blood 2005; 105:2802–2811.
90. Chang HK, Gallo RC, Ensoli B. Regulation of cellular gene
expression and function by the human immunodeficiency
virus type 1 Tat protein. J Biomed Sci 1995; 2:189–202.
91. Frankel AD, Pabo CO. Cellular uptake of the tat protein
from human immunodeficiency virus. Cell 1988; 55:1189–
1193.
92. Shutt DC, Soll DR. HIV-induced T-cell syncytia release a two
component T-helper cell chemoattractant composed of Nef
and Tat. J Cell Sci 1999; 112:3931–3941.
93. Koedel U, Kohleisen B, Sporer B, Lahrtz F, Ovod V, Fontana A,
et al. HIV type 1 Nef protein is a viral factor for leukocyte
recruitment into the central nervous system. J Immunol 1999;
163:1237–1245.
94. Ferrantelli F, Cafaro A, Ensoli B. Nonstructural HIV proteins as
targets for prophylactic or therapeutic vaccines. Curr Opin
Biotechnol 2004; 15:543–556.
95. Caputo A, Gavioli R, Ensoli B. Recent advances in the devel-
opment of HIV-1 Tat-based vaccines. Curr HIV Res 2004;
2:357–376.
96. Reiss P, Lange JM, de Ronde A, de Wolf F, Dekker J,
Debouck C, et al. Speed of progression to AIDS and degree
of antibody response to accessory gene products of HIV-1.
J Med Virol 1990; 30:163–168.
97. Rodman TC, To SE, Hashish H, Manchester K. Epitopes for
natural antibodies of human immunodeficiency virus (HIV)-
negative (normal) and HIV-positive sera are coincident with
two key functional sequences of HIV Tat protein. Proc Natl
Acad Sci U S A 1993; 90:7719–7723.
98. Zagury JF, Sill A, Blattner W, Lachgar A, Le BH, Richardson M,
et al. Antibodies to the HIV-1 Tat protein correlated with
nonprogression to AIDS: a rationale for the use of Tat toxoid
as an HIV-1 vaccine. J Hum Virol 1998; 1:282–292.
99. Re MC, Furlini G, Vignoli M, Ramazzotti E, Roderigo G,
De Rosa V, et al. Effect of antibody to HIV-1 Tat protein on
viral replication in vitro and progression of HIV-1 disease
in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995;
10:408–416.
100. Re MC, Vignoli M, Furlini G, Gibellini D, Colangeli V,
Vitone F, et al. Antibodies against full-length Tat protein
and some low-molecular-weight Tat-peptides correlate with
low or undetectable viral load in HIV-1 seropositive patients.
J Clin Virol 2001; 21:81–89.
101. Richardson MW, Mirchandani J, Duong J, Grimaldo S,
Kocieda V, Hendel H, et al. Antibodies to Tat and Vpr in
the GRIV cohort: differential association with maintenance of
long-term non-progression status in HIV-1 infection. Biomed
Pharmacother 2003; 57:4–14.
102. Demirhan I, Chandra A, Mueller F, Mueller H, Biberfeld P,
Hasselmayer O, et al. Antibody spectrum against the viral
transactivator protein in patients with human immunodefi-
ciency virus type 1 infection and Kaposi’s sarcoma. J Hum
Virol 2000; 3:137–143.
103. Krone WJ, Debouck C, Epstein LG, Heutink P, Meloen R,
Goudsmit J. Natural antibodies to HIV-tat epitopes and ex-
pression of HIV-1 genes in vivo. J Med Virol 1988; 26:261–
270.
104. Butto S, Fiorelli V, Tripiciano A, Ruiz-Alvarez MJ, Scoglio A,
Ensoli F, et al. Sequence conservation and antibody cross-
recognition of clade B human immunodeficiency virus (HIV)
type 1 Tat protein in HIV-1-infected Italians, Ugandans, and
South Africans. J Infect Dis 2003; 188:1171–1180.
105. Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A,
Scoglio A, et al. The presence of anti-Tat antibodies is
predictive of long-term nonprogression to AIDS or severe
immunodeficiency: findings in a cohort of HIV-1 serocon-
verters. J Infect Dis 2005; 191:1321–1324.
2260 AIDS 2006, Vol 20 No 18
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
106. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN,
Habeeb K, et al. The HIV-1 regulatory proteins Tat and Rev
are frequently targeted by cytotoxic T lymphocytes derived
from HIV-1-infected individuals. Proc Natl Acad Sci U S A
2001; 98:1781–1786.
107. Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P,
Klein I, et al. Identification of human immunodeficiency virus
type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-
based cytotoxic T-lymphocyte responses for AIDS vaccine
design. J Virol 2001; 75:9210–9228.
108. Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ.
Comprehensive analysis of human immunodeficiency virus
type 1 (HIV-1)-specific gamma interferon-secreting CD8R
T cells in primary HIV-1 infection. J Virol 2003; 77:6867–6878.
109. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF,
Gaolekwe S, et al. Magnitude and frequency of cytotoxic
T-lymphocyte responses: identification of immunodominant
regions of human immunodeficiency virus type 1 subtype C.
J Virol 2002; 76:10155–10168.
110. van Baalen CA, Schutten M, Huisman RC, Boers PH, Gruters
RA, Osterhaus AD. Kinetics of antiviral activity by human
immunodeficiency virus type 1-specific cytotoxic T lympho-
cytes (CTL) and rapid selection of CTL escape virus in vitro.
J Virol 1998; 72:6851–6857.
111. Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS,
et al. Determinants of human immunodeficiency virus type 1
escape from the primary CD8R cytotoxic T lymphocyte
response. J Exp Med 2004; 200:1243–1256.
112. Cao J, McNevin J, Malhotra U, McElrath MJ. Evolution of
CD8R T cell immunity and viral escape following acute HIV-
1 infection. J Immunol 2003; 171:3837–3846.
113. Allen TM, O’Connor DH, Jing P, Dzuris JL, Mothe BR,
Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select
for SIV escape variants during resolution of primary viraemia.
Nature 2000; 407:386–390.
114. O’Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds
E, et al. Acute phase cytotoxic T lymphocyte escape is a
hallmark of simian immunodeficiency virus infection. Nat
Med 2002; 8:493–499.
115. Tikhonov I, Ruckwardt TJ, Hatfield GS, Pauza CD. Tat-neu-
tralizing antibodies in vaccinated macaques. J Virol 2003;
77:3157–3166.
116. Ramakrishna L, Anand KK, Mohankumar KM, Ranga U. Codon
optimization of the tat antigen of human immunodeficiency
virus type 1 generates strong immune responses in mice
following genetic immunization. J Virol 2004; 78:9174–9189.
117. Opi S, Peloponese JM Jr, Esquieu D, Campbell G, De MJ,
Walburger A, et al. Tat HIV-1 primary and tertiary structures
critical to immune response against non-homologous var-
iants. J Biol Chem 2002; 277:35915–35919.
118. Kuiken C, Foley B, Hahn B, Korber B, McCutchan F, Marx JW,
et al. Human retroviruses and AIDS: a compilation and analysis
of nucleic acid and amino acid sequences. Los Alamos, New
Mexico: Los Alamos National Laboratory.
119. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F,
Cafaro A, et al. Native HIV-1 Tat protein targets monocyte-
derived dendritic cells and enhances their maturation, func-
tion, and antigen-specific T cell responses. J Immunol 2002;
168:197–206.
120. Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A,
Canella A, et al. HIV-1 tat protein modulates the generation
of cytotoxic T cell epitopes by modifying proteasome com-
position and enzymatic activity. J Immunol 2004; 173:3838–
3843.
121. Remoli AL, Marsili G, Perrotti E, Gallerani E, Ilari R, Nappi F,
et al. Intracellular HIV-1 Tat protein represses constitutive
LMP2 transcription increasing proteasome activity by inter-
fering with the binding of IRF-1 to STAT1. Biochem J 2006;
396:371–380.
122. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein
of human immunodeficiency virus type 1, a growth factor for
AIDS Kaposi sarcoma and cytokine-activated vascular cells,
induces adhesion of the same cell types by using integrin
receptors recognizing the RGD amino acid sequence.
Proc Natl Acad Sci U S A 1993; 90:7941–7945.
123. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S,
Caputo A, et al. Vaccination with DNA containing tat
coding sequences and unmethylated CpG motifs protects
cynomolgus monkeys upon infection with simian/human im-
munodeficiency virus (SHIV89.6P). Vaccine 2001; 19:2862–
2877.
124. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D,
Baroncelli S, et al. Control of SHIV-89.6P-infection of cyno-
molgus monkeys by HIV-1 Tat protein vaccine. Nat Med
1999; 5:643–650.
125. Caputo A, Betti M, Altavilla G, Bonaccorsi A, Boarini C,
Marchisio M, et al. Micellar-type complexes of tailor-
made synthetic block copolymers containing the HIV-1
tat DNA for vaccine application. Vaccine 2002; 20:2303–
2317.
126. Betti M, Voltan R, Marchisio M, Mantovani I, Boarini C,
Nappi F, et al. Characterization of HIV-1 Tat proteins mutated
in the transactivation domain for prophylactic and therapeu-
tic application. Vaccine 2001; 19:3408–3419.
127. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory
cytokines induce AIDS–Kaposi’s sarcoma-derived spindle
cells to produce and release basic fibroblast growth factor
and enhance Kaposi’s sarcoma-like lesion formation in nude
mice. J Immunol 1995; 154:3582–3592.
128. Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E,
Moretti S, Sernicola L, et al. Long-term protection against
SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus
monkeys. Vaccine 2004; 22:3258–3269.
129. Ensoli B, Cafaro A. HIV-1 Tat vaccines. Virus Res 2002; 82:
91–101.
130. Various authors. Forum in immunology: rational vaccination
strategies against AIDS. Microbes Infect 2005; 7:1385–1452.
Preventive and therapeutic Tat vaccine trials Ensoli et al. 2261
